Generic Medicine Info
May be taken with or without food. May be taken w/ food or milk to avoid stomach upset.
Acute intermittent porphyria.
Special Precautions
Patients with depression, suicidal tendencies, history of drug abuse or potential for drug dependency, hypoadrenalism, respiratory disease. Debilitated patients. Avoid abrupt withdrawal. Children and elderly. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness or reduced alertness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum primidone and phenobarbital levels, CBC; signs of depression, suicidal ideation and behaviours, neurological status; serum folate levels; bone density (long-term therapy). Obtain comprehensive metabolic panel at 6-month intervals to compare with baseline at the start of therapy.
Adverse Reactions
Significant: Suicidal ideation and behaviour; rarely, megaloblastic anaemia and blood dyscrasias; decreased serum folate and vitamin D levels (long-term therapy). Eye disorders: Visual disturbances, diplopia. Gastrointestinal disorders: Nausea, vomiting. General disorders and administration site conditions: Fatigue. Immune system disorders: Rarely, exfoliative dermatitis, SLE. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Arthralgia, Dupuytren's contracture, osteomalacia. Nervous system disorders: Drowsiness, headache, dizziness, nystagmus, ataxia, vertigo. Psychiatric disorders: Apathy, listlessness, personality change, hyperirritability. Reproductive system and breast disorders: Sexual impotency. Skin and subcutaneous tissue disorders: Maculopapular, morbilliform or scarlatiniform rashes
Potentially Fatal: Rarely, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug Interactions
May have increased serum concentration with CYP3A4 inhibitors (e.g. chloramphenicol, felbamate, nelfinavir, metronidazole, Na valproate). May increase metabolism resulting in lower serum concentration and shorter half-life of androgens, β-antagonists, carbamazepine, chloramphenicol, clozapine, corticosteroids, cyclophosphamide, ciclosporin, dicoumarins, digitoxin, doxycycline, ethosuximide, etoposide, felbamate, granisetron, lamotrigine, losartan, methadone, metronidazole, mianserin, montelukast, nelfinavir, nimodipine, oral contraceptives, oxcarbazepine, phenytoin, quinidine, rocuronium, Na valproate, tiagabine, theophyllines, topiramate, TCAs, vecuronium, warfarin, zonisamide. May increase the hepatotoxicity of paracetamol. Additive CNS depressant effect with other CNS depressant (e.g. barbiturates, opiates).
CIMS Class
ATC Classification
N03AA03 - primidone ; Belongs to the class of barbiturates and derivatives antiepileptics.
Disclaimer: This information is independently developed by CIMS based on primidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in